Le Lézard
Classified in: Business
Subjects: REL, SRI

JLens Receives $10 Million Impact Investment from Leichtag Foundation


NEW YORK, Oct. 24, 2018 /PRNewswire/ -- The Leichtag Foundation has awarded a $10 million challenge impact investment to JLens' Jewish Advocacy Strategy, a Jewish values-aligned investment offering that advocates with companies on Jewish communal concerns - religious tolerance and coexistence, social and environmental issues, and support for Israel. Jewish institutions have invested nearly $50 million in the strategy to date.

Values-based investing, also known as impact investing or socially responsible investing, pursues financial return on capital while also generating a positive impact. According to the Global Sustainable Investment Alliance, the field represents over $22 trillion, or 26% of all professionally managed assets.

The Encinitas, California based Leichtag Foundation aims to bring the full balance of its assets 100% in line with the foundation's values and strategic mission within the next seven years.

Charlene Seidle, Leichtag's executive vice-president, noted, "Aside from the tremendous impact generated by JLens' advocacy with public companies, the strategy fits well financially with our overall investment policy and was reviewed by our investment consultants. We want to encourage other Jewish institutions to consider values-based investing, and JLens' US Equity ESG market-rate investment is a great entry point."

"JLens represents the Jewish community in the rapidly growing and increasingly influential values-based investing and corporate social responsibility movements," explained Julie Hammerman, JLens' executive director. "Leichtag's challenge investment comes at the perfect time to strengthen JLens voice in an area where Jewish leadership is essential."

JLens conducts shareholder advocacy with the approximately 300 companies held in the strategy to pursue positive changes on a range of concerns including the opioid crisis, human trafficking, clean energy, animal welfare, and religious tolerance. Additionally, JLens provides factual information on Israel to counter the false narrative presented to companies and investors by the BDS campaign.

According to Rabbi Jacob Siegel, JLens' Director of Engagement, "The values-based investing field is an exciting area to explore Jewish teachings in a modern context."

About:
JLens (www.jlensnetwork.org) is an investor network that explores a Jewish lens on investing. JLens oversees the Jewish values-overlay and advocacy for the Jewish Advocacy Strategy managed by Lens Investments. Follow: Twitter, Facebook, LinkedIn

The Leichtag Foundation (www.leichtag.org) honors the legacy of Lee and Toni Leichtag through igniting and inspiring vibrant Jewish life, advancing self-sufficiency and stimulating social entrepreneurship in coastal North San Diego County and Jerusalem.

 

SOURCE JLens


These press releases may also interest you

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") and certain officers. The class action, filed in the United States District Court for the Southern District of...

at 11:00
The Georgia Trust for Historic Preservation presented 26 awards recognizing the best of preservation in Georgia during its 47th annual Preservation Awards ceremony in Athens, Ga. Security Federal Bank in Augusta received the Marguerite Williams...

at 11:00
Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against VinFast Auto Ltd. ("VinFast" or the "Company") f/k/a Black Spade Acquisition Co., ("Black Spade") and certain officers. The class action, filed in the United States District...

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext....

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") and certain officers.  The class action, filed in the United States District Court for the Southern District of...



News published on and distributed by: